Ticker Launch
Sign inTry it free

IPO · GDTC

CytoMed Therapeutics Ltd

Formerly CytoMed Therapeutics Pte. Ltd.

CytoMed Therapeutics Ltd (GDTC) priced its initial public offering on Apr 17, 2023 at $4.00 per share, raising $9.6M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $43.8M. Benchmark was lead-left underwriter. Ellenoff Grossman & Schole and Opal Lawyers advised the company and Sheppard Mullin advised the underwriters.

CytoMed Therapeutics Ltd is a Singapore pre-clinical biopharmaceutical company using licensed proprietary technologies to create cell-based immunotherapies for human cancers, inspired by the clinical success of CAR-T in treating hematological malignancies.

Status
IPO
Ticker
GDTC
Exchange
Nasdaq Capital Market
Priced
Apr 17, 2023
IPO price
$4.00
Raised
$9.6M
Market cap at IPO price
$43.8M
First filed
Nov 18, 2022
Underwriters
Benchmark
Company counsel
Ellenoff Grossman & Schole and Opal Lawyers
Underwriters' counsel
Sheppard Mullin
Sector
Biotech & pharma
Country / state
Singapore

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.

More on this listing for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other Biotech & pharma IPOs in 2023